Department of Pediatrics, Tongcheng People's Hospital of Anhui Province, Tongcheng, Anhui 231400, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Nov 15;23(11):1161-1168. doi: 10.7499/j.issn.1008-8830.2108078.
To systematically evaluate the effect of gonadotropin-releasing hormone analogue (GnRHa) treatment on the final adult height of children over 6 years of age with central precocious puberty (CPP) or early and fast puberty (EFP).
PubMed, MEDLINE, Embase, Cochrane Library, CNKI, and Wanfang Data were searched for related articles on GnRHa treatment for children with CPP or EFP. Stata 12.0 software was used to perform a Meta analysis of related data.
A total of 10 studies were included, and the total sample size was 720 children, with 475 children in the GnRHa treatment group and 245 children in the control group. The Meta analysis showed that compared with the control group, the GnRHa treatment group had significantly better final adult height (=3.30, 95%: 2.49-4.12, <0.001), standard deviation score of final adult height (=0.51, 95%: 0.29-0.73, <0.001), and height gain (=2.89, 95%: 2.17-3.60, <0.001). No severe adverse events were reported in these studies.
GnRHa treatment is safe and effective in improving the final adult height of children over 6 years of age with CPP or EFP.
系统评价促性腺激素释放激素类似物（GnRHa）治疗对中枢性性早熟（CPP）或早发性青春期（EFP）患儿 6 岁以上最终成年身高的影响。
检索 PubMed、MEDLINE、Embase、Cochrane 图书馆、中国知网（CNKI）和万方数据中关于 GnRHa 治疗 CPP 或 EFP 患儿的相关文章。采用 Stata 12.0 软件对相关数据进行 Meta 分析。
共纳入 10 项研究，总样本量为 720 例儿童，GnRHa 治疗组 475 例，对照组 245 例。Meta 分析结果显示，与对照组相比，GnRHa 治疗组的最终成年身高（=3.30，95%CI：2.49-4.12，<0.001）、最终成年身高标准差评分（=0.51，95%CI：0.29-0.73，<0.001）和身高增长（=2.89，95%CI：2.17-3.60，<0.001）均显著更好。这些研究均未报告严重不良事件。
GnRHa 治疗对 CPP 或 EFP 患儿 6 岁以上的最终成年身高改善安全有效。
